Pioneering mutant-selective cancer therapies
Scorpion Therapeutics (scorpiontx.com) earns a Brand Analyzer score of 64 out of 100, placing it in the Developing tier among Healthcare brands. Among 2305 Healthcare brands analyzed, Scorpion Therapeutics ranks in the 28th percentile (category average 68, leader 95). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 80/100, Digital Presence 82/100, Visual Identity 80/100, Messaging Clarity 100/100, Trust Foundation 72/100, AI Discoverability 41/100, Brand Authority 11/100.
Scorpion Therapeutics is a precision oncology company founded in 2020 and based in Boston, United States. It focuses on developing mutant-selective PI3Kα inhibitors, with its lead candidate STX-478 designed to treat hormone-positive breast cancer. STX-478 targets the PI3Kα pathway specifically in cancerous cells while sparing healthy tissue, aiming to deliver deeper pathway inhibition and improved tolerability compared to existing treatments in this class.
| Brand Name | Scorpion Therapeutics |
|---|---|
| Domain | scorpiontx.com |
| Industry | Healthcare |
| Founded | 2020 |
| Headquarters | Boston, United States |
| Main Competitors | Relay Therapeutics, Kronos Bio, Novartis (84/100), Pfizer (89/100), Iqvia, Recursion Pharmaceuticals |
Moz Domain Authority 33/100 vs category average 29 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts." (No meta description. OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description, og:image, og:type, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on Instagram, LinkedIn, YouTube, GitHub; no detected presence on Facebook, X (Twitter) - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Scorpion Therapeutics scores 22/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Scorpion Therapeutics has a weak AI-visibility profile at 22/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (35/100) and its weakest is trust (12/100). It benefits from a Wikidata knowledge-graph entry and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 33/100 and thin schema.org structured data.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Scorpion Therapeutics's main competitors include Relay Therapeutics, Kronos Bio, Novartis, Pfizer (89/100), Iqvia. These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Scorpion Therapeutics official site
Scorpion Therapeutics and Pfizer are competitors in Healthcare. Brand Analyzer scores Scorpion Therapeutics at 64/100 and Pfizer at 89/100. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Scorpion Therapeutics official site
Popular alternatives to Scorpion Therapeutics include Relay Therapeutics, Kronos Bio, Novartis, Pfizer (89/100), Iqvia. Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Scorpion Therapeutics official site
Scorpion Therapeutics' primary product candidate is STX-478, a mutant-selective PI3Kα inhibitor in development for the treatment of hormone-positive breast cancer. STX-478 is designed to selectively inhibit the PI3Kα pathway in tumor cells carrying specific mutations, while avoiding the toxicity associated with inhibiting PI3Kα in healthy tissues. No additional commercial products are referenced in the available information.
Sources: Scorpion Therapeutics official site
Scorpion Therapeutics has low AI-search visibility, scoring 22/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 12, recommendation 35). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Scorpion Therapeutics official site
Scorpion Therapeutics was founded in 2020. Scorpion Therapeutics operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Scorpion Therapeutics develops mutant-selective PI3Kα inhibitors intended to treat hormone-positive breast cancer. Its approach centers on selectively targeting the PI3Kα pathway in cancerous cells while minimizing impact on healthy cells. This selectivity is designed to enable deeper inhibition of the cancer-driving pathway and offer better tolerability than existing therapies. Its lead program, STX-478, embodies this strategy.
Sources: Scorpion Therapeutics official site
Scorpion Therapeutics scores 35/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Scorpion Therapeutics official site
Scorpion Therapeutics is a precision oncology company founded in 2020 and headquartered in Boston, United States. It operates in the healthcare sector and focuses on developing mutant-selective inhibitors targeting specific cancer-driving genetic alterations. Its positioning is as a next-generation precision oncology innovator, with a particular emphasis on the PI3Kα signaling pathway implicated in hormone-positive breast cancer.
Sources: Scorpion Therapeutics official site
Scorpion Therapeutics can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Scorpion Therapeutics official site
Scorpion Therapeutics is known for developing STX-478, a mutant-selective PI3Kα inhibitor aimed at hormone-positive breast cancer. The compound is distinguished by its ability to target cancerous PI3Kα mutations while sparing normal cells, a design intended to achieve superior efficacy and tolerability relative to earlier-generation PI3Kα inhibitors currently on the market.
Sources: Scorpion Therapeutics official site
According to available information, Scorpion Therapeutics' target audience includes patients with hormone-positive breast cancer who may benefit from PI3Kα-targeted therapies, as well as pharmaceutical partners who may collaborate on or license the company's mutant-selective inhibitor programs. The company is also likely of interest to oncologists and clinical investigators involved in breast cancer treatment research.
Sources: Scorpion Therapeutics official site
Ranked closest to Scorpion Therapeutics: Sapreme (64/100), PsiqueMais (64/100), Scrubs N Stuff (64/100), SpecialtyCare (64/100).
A step up - brands to learn from: Zipari by mPulse (71/100), Zaina AI (71/100).
Category leader: Dassault Systèmes (95/100).